<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322866</url>
  </required_header>
  <id_info>
    <org_study_id>SC1402</org_study_id>
    <nct_id>NCT02322866</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety &amp; Efficacy of Sarecycline in Treatment of Acne</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline
      compared to placebo in the treatment of moderate to severe facial acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absolute Change in Inflammatory Lesion Count</measure>
    <time_frame>Baseline to week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Global Assement (IGA) Success</measure>
    <time_frame>Baseline to week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as at least a 2-point decrease from baseline and a score of clear/0 or almost clear/1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Inflammatory Lesion Counts</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Sarecycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarecycline tablets, 1.5 mg/kg/day, taken orally once daily for 12 weeks. Taken at approximately the same time each day, at least 1 hour prior to, or 2 hours after eating.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo takets, taken orally once daily for 12 weeks.  Taken at approximately the same time each day, at least 1 hour prior to, or 2 hours after eating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarecycline</intervention_name>
    <description>1.5 mg/kg/day taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating</description>
    <arm_group_label>Sarecycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent or assent form

          -  Male/female, 9 to 45 years of age, inclusive

          -  Body weight between 33 and 136 kg, inclusive

          -  Facial acne vulgaris with:

          -  20-50 inflammatory lesions (papules, pustules and nodules)

          -  30-100 noninflammatory lesions (open and closed comedones)

          -  No more than 2 nodules

          -  IGA score of moderate (3) or severe (4)

          -  Negative urine pregnancy test at baseline - females of childbearing potential

          -  Agrees to use an effective method of contraception throughout the study

          -  Refrain from use of any other acne medications and medicated cleansers, and avoid
             excessive sun exposure and tanning booths for duration of study

          -  Able to fulfill the requirements of protocol, indicated willingness to participate in
             the study and agrees to all study procedures (including mandatory photography) by
             providing written informed consent/assent and an authorization to disclose protected
             health information (PHI)

        Exclusion Criteria:

          -  Has a dermatological condition of the face that could interfere with the clinical
             evaluations

          -  Has a history of any of the following:

          -  Allergy to tetracycline-class antibiotics or to any ingredient in the study drug

          -  Pseudomembranous colitis or antibiotic-associated colitis

          -  Treated for any type of cancer within the last 6 months

          -  Has known resistance to other tetracyclines

          -  Has receive any of the following treatments within 12 weeks of screening:

          -  Systemic retinoids

          -  Systemic corticosteroids

          -  Androgens/anti-androgenic therapy (eg, anabolic steroids, spironolactone)

          -  Non-medicated procedures for the treatment of acne (eg, laser, light or ThermaClear)

          -  Has used any acne affecting treatment without an appropriate washout period

          -  Has initiated hormonal contraceptive use within 12 weeks prior to screening or plans
             to initiate or switch hormonal contraceptive products during the study period

          -  Is pregnant, lactating or planning a pregnancy during the study period

          -  Has any other disorder causing hyperandrogenism including, but not limited to
             polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital
             adrenal hyperplasia

          -  Has drug-induced acne

          -  Has significant intercurrent illness, psychiatric disposition or other factors that,
             in the opinion of the Investigator or Medical Monitor, precludes participation in the
             study

          -  Is currently participating, or has participated within 30 days prior to the screening
             period in an investigational drug or device study

          -  Has previously participated in any clinical trial involving the use of sarecycline

          -  Is judged by the Investigator to be unsuitable for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vilma Sniukiene, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Densingh Bright, PhD, MBA</last_name>
    <phone>866-369-5227</phone>
    <phone_ext>8742</phone_ext>
    <email>Densingh.bright@frx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #206)</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #236)</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #245)</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #234)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #209)</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #215)</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #204)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>82123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #243)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #222)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #237)</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #226)</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #238)</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #202)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #211)</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #247)</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #241)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #228)</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #203)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #242)</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #210)</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #213)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #217)</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #248)</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #205)</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #235)</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #227)</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #221)</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #231)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #239)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #208)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #240)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #230)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #229)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #218)</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #214)</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #219)</name>
      <address>
        <city>Fountain Inn</city>
        <state>South Carolina</state>
        <zip>29644</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #225)</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #216)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #220)</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #201)</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #223)</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #207)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #224)</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #212)</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #244)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #246)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #233)</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Research Site (Site #232)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 31, 2015</lastchanged_date>
  <firstreceived_date>December 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
